The safety and immunogenicity of a new tuberculosis (TB) vaccine, MVA85A, in healthy volunteers who are infected with human immunodeficiency virus (HIV): an open label phase I study.
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2014
At a glance
- Drugs MVA 85A (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 19 Dec 2009 The Wellcome Trust added as trial sponsor as reported by ISRCTN: Current Controlled Trials.